Jagforce SB 65 Capsule contains Itraconazole 65 mg, a broad-spectrum triazole antifungal agent used in the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to fungal cell death. This medication is indicated for the management of systemic and superficial mycoses, including aspergillosis, histoplasmosis, blastomycosis, onychomycosis, and candidiasis. Jagforce SB 65 Capsule is particularly effective against dermatophytes, yeasts, and molds. It is administered orally, with absorption enhanced when taken with food. The drug is metabolized primarily in the liver via the cytochrome P450 system, necessitating caution in patients with hepatic impairment and potential drug interactions. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Liver function tests should be monitored during prolonged therapy. Jagforce SB 65 Capsule should be used under medical supervision, with dosage adjustments based on the severity of infection and patient response. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals. This capsule provides an effective therapeutic option for managing difficult-to-treat fungal infections.